Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 348

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 348
---
 study (phase 3 study evaluating monalizumab in combination with cetuximab in patients with squamous cell carcinoma of the head and neck and previously treated with chemotherapy).

F-64

• Obtaining positive Phase 2 results for a product in the Company's portfolio.

•The start of a first clinical trial for a product in the Company's portfolio

The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below:

• Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach;

• Adjustment of the estimation by applying expected turnover rates.

Expenses were € 1,577 1,161 1,162

Free performance shares 2022 (AGA Perf Employees 2022-1 / AGA Perf Management 2022-1)

Free performance shares granted in 2022 are subject to share market capitalization and three

• The filing and approval of a BLA (Biologic License Application) application filed with the Food and Drug Administration ("FDA") in the United States or the European Medicine Agency ("EMEA") in Europe for one

• The start of a first clinical trial for a product from the Company's portfolio.

• The conclusion of a collaboration or license agreement.

The fair value of these free performance shares is based on a third-party valuation report. The valuation method used to estimate the fair value of these free performance shares is presented below:

• Estimation of the expectation of gain associated with internal and share price conditions, made on the basis of a CAPM model of the share price using a Monte Carlo approach;

• Adjustment of the estimation by applying expected turnover rates.

Expenses were € 46 1,157 888

AGA Bonus 2022-1

AGA Bonus 2022 were granted to the Executive members Committee who opted for these compensation plans. For each recipient, the number of shares definitely acquired is equal to the cash equivalent of 50 50 100

Expenses were € 499 No

AGA New-members 2023-1

Expenses were € 3 19

F-65

Free performance shares 2023 (AGA Perf Employees 2023-1 / AGA Perf Management 2023-1)

Free performance shares granted in 2023 are subject to the Company's market capitalization and